Clinical trial NCT01064440: Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
Official title: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 (Engensis) in Subject With Critical Limb Ischemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Critical Limb Ischemia
Keywords: Painful legs
Ischemic legs
Treatment for Claudication
Gene therapy
Lead sponsor: Helixmith Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2010-02-08
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate whether intramuscular injections of VM202 into the calf is safe and effective in the treatment of critical limb ischemia.

Detailed description: In the absence of revascularization options, most patients with CLI require amputation within 6 months. Patients requiring major amputation face a diminished quality of life, an unfavorable natural history and need extensive resources for their post-amputation rehabilitation and course. The 1-year amputation-free survival rate for patients diagnosed with CLI is 45%; the mortality rate is approximately 25% and may be as high as 45% in those who have undergone amputation. Management of this end-stage disease process consumes a significant amount of healthcare resources. Clearly, new therapeutic approaches are required.

Hepatocyte growth factor (HGF) has been shown to be a potent angiogenic growth factor stimulating the growth of endothelial cells and migration of vascular smooth muscle cells. Because of its pluripotent capabilities, increasing the availability of HGF in ischemic tissues to achieve therapeutic angiogenesis has been a growing area of research.

This study will use VM202, which is a DNA plasmid that contains novel genomic cDNA hybrid human HGF coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723. As there are currently no approved drugs that can reverse CLI and as most patients have exhausted surgical and endovascular intervention options, inducing angiogenesis in the affected limb with VM202 may result in an increase in tissue perfusion, which, in turn improve wound healing, reduce pain and improve limb salvage rates.

Eligibility criteria: Inclusion Criteria:

* Male or female, between 18 and 90 years of age;
* Diagnosis of critical limb ischemia (Rutherford Class 4 or 5), including:

  * A resting ankle systolic pressure (in either the dorsalis pedis or posterior tibial arteries) of ≤ 70 mmHg in the affected limb; or
  * A resting toe systolic pressure of ≤ 50 mmHg in the affected limb; or
  * For patients in which measurement of ankle systolic pressure is not feasible (e.g. vessel calcification and non-compressibility); TcPO2 ≤ 30 mmHg;
* Poor or suboptimal candidate for bypass graft surgery or percutaneous angioplasty;
* Pain at rest, and/or ischemic ulcers, and/or focal gangrene (\< 3 cm2) for a minimum of 2 weeks,
* Significant stenosis (≥ 75%) of one or more of the following arteries: superficial femoral, popliteal, or two or more infra-popliteal arteries as verified by angiography within 12 months prior to enrollment;
* Be willing to maintain current drug therapy for peripheral arterial disease throughout the course of the study including an anti-platelet and statin treatment unless not tolerated;
* Clinically stable on optimized medical regimen for \>30 days
* Be capable of understanding and complying with the protocol and signing the informed consent document prior to being subjected to any study related procedures;
* Women who are surgically sterile or at least 1 year postmenopausal or who have been practicing adequate contraception for at least 12 weeks prior to entering the study. If the subject is of child-bearing potential, she must have a negative urine pregnancy test result prior to study enrollment and must agree to repeat pregnancy screening tests during the study. If the subject or the subject's partner(s) is of child bearing potential, the subject and the subject's partner(s) must agree to use a "double barrier" method of birth control while participating in this study.

Exclusion Criteria:

* Subjects who have undergone a successful revascularization procedure or sympathectomy within 12 weeks prior to study entry. A clinically unsuccessful revascularization procedure is defined as one in which:

  * the target vessel re-occludes (≥50%, as verified by a second angiogram. Duplex ultrasonography can be used to determine vessel patency if the patient cannot tolerate a second angiogram), or
  * the target vessel remains patent, but there is no resolution of symptoms 6 weeks after the procedure (e.g. no evidence of ulcer healing, no improvement in pressures, no reduction in resting pain);
* Subjects that will require an amputation in the target leg within 4 weeks of randomization;
* Subjects with evidence of active infection (e.g., cellulitis, osteomyelitis) or deep ulceration exposing bone or tendon in the extremity planned for treatment;
* Heart Failure with a NYHA classification of III or IV;
* Stroke (NIH scale \>2) or myocardial infarction within last 3 months;
* Unstable angina
* Uncontrolled hypertension defined as sustained systolic blood pressure (SBP) \> 200 mmHg or diastolic BP (DBP) \> 110 mmHg at baseline/screening evaluation;
* Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that preclude standard ophthalmologic examination;
* Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's disease);
* Subjects with advanced liver disease including decompensated cirrhosis, jaundice, ascites or bleeding varices;
* Subjects currently receiving immunosuppressive medications chemotherapy, or radiation therapy;
* Positive HIV or HTLV at screening;
* Active Hepatitis B or C infection as determined by Hepatitis B surface antibody (HBsAb), Hepatitis B core antibody (IgG and IgM; HBcAb), Hepatitis B surface antigen (HBsAg) and Hepatitis C antibodies (Anti-HCV), at Screening;
* Specific laboratory values at Screening including: Hemoglobin \< 8.0 g/dL, WBC \< 3,000 cells per microliter, platelet count \<75,000/mm3, AST and/or ALT \> 3 times the upper limit of normal or any other clinically significant lab abnormality which in the opinion of the investigator should be exclusionary;
* Patients with a recent history (\< 5 years) of or new screening finding of malignant neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if excised and no evidence of recurrence); patients with family history of colon cancer in any first degree relative are excluded unless they have undergone a colonoscopy in the last 12 months with negative findings;
* Elevated PSA unless prostate cancer has been excluded;
* Subjects with any co- morbid conditions likely to interfere with assessment of safety or efficacy or with an estimated life expectancy of less than 6 months
* Subjects requiring \> 81 mg daily of acetylsalicylic acid; If \> 81 mg are taken at screening, subjects may be enrolled if willing/able to switch to another medication;
* Subjects requiring regular COX-2 inhibitor drug(s) or high dose steroids (excepting inhaled steroids);
* Major psychiatric disorder in past 6 months;
* History of drug or alcohol abuse / dependence in the past 2 years;
* Use of an investigational drug or treatment in past 12 months; concurrent participation in investigational protocol or unapproved therapeutics and
* Unable or unwilling to give informed consent.

Primary outcomes:
measure: Number of Participants With Treatment-emergent Adverse Events Following Intramuscular Administration of 8 and 16 mg Engensis (VM202) or Placebo in Subjects With Critical Limb Ischemia.
timeFrame: Baseline - Days 0, 14, 28, 42, 49, 90, 180, 270 and 365
measure: Change From Baseline in Visual Analog Scale (VAS) for Pain
timeFrame: Days 0, 90, 180, 270, and 365
Secondary outcomes:
measure: Change From Baseline in Tissue Oxygenation (TcPO2) for the Dorsal Surface of the Foot Following Engensis (VM202) or Placebo
timeFrame: Day 0 to Days 180, 270, and 365
measure: Change From Baseline in Hemodynamic Assessment for Ankle Brachial-Index (mmHg) for the Index Leg
timeFrame: Days 0, 28, 90, 180, 270, and 365
measure: Change From Baseline in Perfusion of the Occluded Target Artery by Magnetic Resonance Angiogram (MRA)
timeFrame: Day 0 to Days 180 and 270
measure: Subjects With 100% Wound Healing
timeFrame: Days 0, 14, 28, 42, 49, 90, 180, 270, and 365
measure: Change From Baseline in the Vascular Quality of Life Total Score
timeFrame: Days 0, 90, 270, and 365
measure: Number of Subjects With Major, Lower Leg, Amputations During the Trial
timeFrame: Day 0 through Day 365
measure: The Number of Deaths During the Trial
timeFrame: Day 0 to Day 365
measure: Change From Baseline in Visual Analog Scale (VAS) for Pain at 9 Months- by Sex
timeFrame: Days 0 (baseline), 9 months (Day 270)
measure: Change From Baseline in Visual Analog Scale (VAS) for Pain at 9 Months- by Renal Dysfunction Status
timeFrame: Days 0 (baseline), 9 months (Day 270)
measure: Change From Baseline in Visual Analog Scale (VAS) for Pain at 9 Months- by Diabetes Status
timeFrame: Days 0 (baseline), 9 months (Day 270)
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Cardiology PC
state: Alabama
city: Orange
country: United States
facility: Vascular and Interventional Specialist of Orange County
state: California
city: Chicago
country: United States
facility: Northwestern Memorial Hospital
state: Illinois
city: Indianapolis
country: United States
facility: St. Vincent Medical Group
state: Indiana
city: Boston
country: United States
facility: Boston University School of Medicine
state: Massachusetts
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
city: Saint Louis
country: United States
facility: Saint Louis University
state: Missouri
city: Chapel Hill
country: United States
facility: UNC School of Medicine
state: North Carolina
city: Toledo
country: United States
facility: Jobst Vascular
state: Ohio
city: Oklahoma City
country: United States
facility: University of Oklahoma HSC
state: Oklahoma
city: Houston
country: United States
facility: Texas Heart Institute
state: Texas
city: Houston
country: United States
facility: The Methodist Hospital
state: Texas
city: Salt Lake City
country: United States
facility: University of Utah
state: Utah
city: Seoul
country: Korea, Republic of
facility: Seoul National University
state: Jongno-gu
city: Seoul
country: Korea, Republic of
facility: Yonsei University Health System. Severance Cardiovascular Hospital
state: Seodaemun-gu
city: Seoul
country: Korea, Republic of
facility: Ewha Womans University Medical Center
state: YangCheon-ku
Study officials:
affiliation: Texas Heart Institute
name: Emerson Perin, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kibbe MR, Hirsch AT, Mendelsohn FO, Davies MG, Pham H, Saucedo J, Marston W, Pyun WB, Min SK, Peterson BG, Comerota A, Choi D, Ballard J, Bartow RA, Losordo DW, Sherman W, Driver V, Perin EC. Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia. Gene Ther. 2016 Mar;23(3):306-12. doi: 10.1038/gt.2015.110. Epub 2015 Dec 8.